The human brain is one of medicine’s most complex and undiscovered frontiers. Unlike a broken bone that may show clearly on an X-ray, the earliest signs of neurodegenerative diseases often hide in subtle changes that can be incredibly difficult to detect, even for experienced clinicians. These diseases affect one in three people during their lifetime,1 yet the time from symptom onset to diagnosis can stretch from one to four years—precious time that could be used for intervention and care planning.
This diagnostic challenge isn’t just a clinical problem—it’s a human one. Families spend months in uncertainty, patients navigate a fragmented healthcare experience, and health systems rely on reader-dependent workflows that can produce inconsistent results. Meanwhile, neurodegenerative diseases affect more than 57 million people globally—a figure that is expected to double every 20 years.2
But what if we could change this? What if brain health could become as visible, measurable, and meaningful as other aspects of healthcare we’ve already transformed with AI?
The challenge we face
Neurodegenerative disease detection remains one of healthcare’s most stubborn challenges. Early brain changes are subtle and hard to distinguish from normal aging. The workflow is complex and heavily dependent on individual clinician experience, leading to inconsistent results. High manual workloads force clinical staff to spend significant time on repetitive tasks, slowing down decision-making and delaying timely intervention.
These aren’t just operational inefficiencies—they represent missed opportunities to help patients and families prepare for what’s ahead, access appropriate care, and make informed decisions about their future.
A new approach to brain health
At DeepHealth, we believe the same AI-powered approach that’s revolutionizing cancer detection can transform how we identify and monitor signs of potential neurodegenerative disease. That’s why we’ve put years of innovation and experience into building and expanding our Neuro Suite—an AI-powered portfolio of modular solutions that aims to automate and standardize neuroimaging analysis. Featuring operational and clinical tools that work in unison, the components of Neuro Suite are designed to provide a comprehensive brain health assessment that is based on validation in clinical practice.
A flagship component of the Neuro Suite is Brain Health,3 which received FDA clearance in 2025. Our AI-powered white matter hyperintensity (WMH) detection and segmentation is designed to enable earlier and more accurate diagnosis of neurodegenerative diseases. The solution provides deep learning-based quantification and localization to support objective assessment, with automatic longitudinal analysis to track changes over time. By harnessing AI to analyze subtle patterns in brain imaging, this technology aims to enhance clinical review with automatic localization of WMH and precise boundary segmentation for accurate assessment.
Brain Age is also part of the Neuro Suite offering, delivering AI-powered brain structure segmentations and volumetric measurements built on FreeSurfer—an open source neuroimaging toolkit developed by the Laboratory for Computational Neuroimaging at the Athinoula A. Martinos Center for Biomedical Imaging, in affiliation with the Department of Radiology at Massachusetts General Hospital, Harvard Medical School, and MIT. Brain Age is designed to provide precise measurements of brain structure volumes, intracranial volume, lobes, hippocampus, and bilateral subcortical structures such as amygdala, putamen, caudate, and thalamus. The solution includes reference centile curves combined with volumetric measurements of brain structures, in addition to smart comparisons to both a healthy reference database to highlight deviations and against prior scans for detecting progression.
Empowering clinicians, providing clarity for patients
Just as AI has revolutionized cancer screening by giving radiologists powerful tools to detect subtle lesions and streamline workflows, the components of Neuro Suite are designed to empower clinicians with added confidence in neurodegenerative disease assessment.
For patients and families, this can mean added clarity where there was once uncertainty. Standardized, quantitative results help clinicians communicate findings more effectively, and longitudinal tracking provides the objective analysis required to visualize changes over time.
For health systems, the Neuro Suite offers something potentially equally valuable—optimized performance at scale. It’s the perfect balance: enabling healthcare systems to simultaneously improve efficiency and reduce costs, all while maintaining quality. The cloud-native architecture, powered by DeepHealth OS, enables flexible deployment across sites. It also delivers automated, simplified reporting designed to reduce variability and save time.
Fighting disease sooner, making innovation accessible
The FDA clearance of Brain Health represents more than a regulatory milestone—it validates the belief that AI can transform the neurodegenerative disease care journey. Identifying signs of potential disease sooner means patients, families, and health systems can act more quickly, creating real impact at scale to advance population health.
This aligns with our broader mission at DeepHealth: empowering breakthroughs in care through imaging. We’re not just building tools; we’re enabling a fundamental shift from reactive to proactive care. Whether it’s screening for cancer or monitoring neurodegenerative changes, our goal is to identify diseases before symptoms emerge, when intervention can be most effective.
Just as importantly, we’re committed to putting these breakthroughs into the hands of all people in all places. The reality is that the most sophisticated tools are only meaningful if they’re available to patients when they need them. That’s why the Neuro Suite is designed not just for clinical excellence, but for practical deployment.
Our offerings are cloud-native and accessible from anywhere, enabling flexible deployment across healthcare sites. They are designed to integrate seamlessly into existing workflows, making adoption straightforward for practices and radiologists.
The future of brain health
The expansion of DeepHealth’s Neuro Suite represents a significant step forward in neurodegenerative disease assessment and management. But this is just the beginning.
As we continue to expand our portfolio of AI-powered solutions across breast, chest, prostate, brain, and thyroid health, we’re building toward a future where comprehensive disease screening becomes the standard of care. A future where the gap between innovation and access continues to narrow, and where more people have the opportunity to detect and address health challenges early.
The human brain may be complex, but AI helps make its health more visible and measurable in ways that may support earlier detection, more confident care, and better disease management for everyone who needs it.
Learn more about DeepHealth’s Neuro Suite
References
- World Health Organization. “Over 1 in 3 people affected by neurological conditions—the leading cause of illness and disability worldwide.” March 14, 2024.
- Imam, F., et al. “The global neurodegeneration proteomics consortium: Biomarker and drug target discovery for common neurodegenerative diseases and aging.” Nature Medicine, 2025. https://doi.org/10.1038/s41591-025-03834-0
- Manufactured by Quantib, BV. Distributed by DeepHealth.
